Takhzyro Approved for Pediatric Hereditary Angioedema
The approval was supported extrapolation of efficacy data from the phase 3 HELP study, along with safety and pharmacodynamic data from the phase 3 SPRING study.
Diagnosis & Disease Information
Investigational CRISPR Therapy Gets Orphan Drug Status for Hereditary Angioedema
Using CRISPR/Cas9 technology, the investigational therapy is designed to edit disease-causing genes inside the human body.
Takhzyro Prefilled Syringe Now Available for Patients With Hereditary Angioedema
The prefilled syringe is provided as a 300mg/2mL (150mg/mL) ready-to-use solution for subcutaneous injection and does not require additional reconstitution or dilution.
- Loading...
Loading...
Next post in News
Loading... 
Loading...